Boston , MA —Research suggests that adding hormonal therapy to standard treatments for prostate cancer can offer real advantages to men with advanced or high-grade disease that has not spread from the gland, according to the January issue of Harvard Men's Health Watch .
Scientists have made great progress in understanding prostate cancer. They've identified the genes that make some men particularly vulnerable to this disease and are starting to pinpoint the lifestyle factors linked to risk. Even the standard treatments have greatly improved. Surgical removal of the gland has become safer, and new techniques can help preserve potency. Innovative forms of radiation therapy allow oncologists to deliver more powerful treatment with fewer side effects. And new forms of hormonal drug therapy can dramatically lower levels of testosterone, which fuels the growth of prostate cells.
Earlier studies suggested that combining hormonal therapy and external beam radiation could reduce the progression of locally advanced cancer more effectively than radiation alone, although men treated surgically did not appear to benefit from adding hormonal treatment. Now three more studies, described in Harvard Men's Health Watch , extend the reach of combination therapy. Two found that adding hormonal therapy can prolong survival in men receiving radiation, and the third reported that hormonal treatment could reduce the progression of disease in men treated with radiation, surgery, or watchful waiting.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.